-+ 0.00%
-+ 0.00%
-+ 0.00%

Erasca notifies availability of press release on updated Phase 1 ERAS-0015 data and trial plans

PUBT·07/13/2026 20:01:23
Listen to the news
Erasca notifies availability of press release on updated Phase 1 ERAS-0015 data and trial plans
  • Erasca released updated preliminary Phase 1 data for pan-RAS molecular glue ERAS-0015 in RAS-mutant solid tumors.
  • At 32 mg QD, 57% unconfirmed ORR at 8 weeks in 2L+ KRAS G12X pancreatic cancer; median relative dose intensity 100%.
  • First ERAS-0015 plus panitumumab dose-escalation cohort cleared at 16 mg with no DLTs; escalation continues at 24 mg.
  • Additional monotherapy, combination data expected in H1 2027; registration-enabling lung trial planned H1 2027, pancreatic Phase 3 in 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Erasca Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607131601PRIMZONEFULLFEED9761205) on July 13, 2026, and is solely responsible for the information contained therein.